MCID: MLG002
MIFTS: 50

Malignant Peritoneal Mesothelioma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Malignant Peritoneal Mesothelioma

MalaCards integrated aliases for Malignant Peritoneal Mesothelioma:

Name: Malignant Peritoneal Mesothelioma 59
Diffuse Malignant Peritoneal Mesothelioma 59
Primary Malignant Peritoneal Mesothelioma 59
Malignant Mesothelioma of Peritoneum 73

Characteristics:

Orphanet epidemiological data:

59
malignant peritoneal mesothelioma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (France),1-9/100000 (Europe),1-9/1000000 (Italy); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 59 ORPHA168811
UMLS via Orphanet 74 C0346109
ICD10 via Orphanet 34 C45.1

Summaries for Malignant Peritoneal Mesothelioma

MalaCards based summary : Malignant Peritoneal Mesothelioma, also known as diffuse malignant peritoneal mesothelioma, is related to peritoneal mesothelioma and adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Malignant Peritoneal Mesothelioma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are MicroRNAs in cancer and Cytoskeletal Signaling. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include t cells, colon and pancreas, and related phenotypes are ascites and weight loss

Related Diseases for Malignant Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Malignant Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 30.5 BAP1 CDKN2A EGFR MUC1 NF2
2 adenocarcinoma 29.2 CDKN2A EGFR MUC1
3 squamous cell carcinoma 29.1 CDKN2A EGFR MUC1
4 lung cancer susceptibility 3 29.0 CDKN2A EGFR MUC1
5 li-fraumeni syndrome 28.9 CDKN2A EGFR
6 renal cell carcinoma, nonpapillary 28.5 EGFR MUC1 VIM
7 peritonitis 11.0
8 transitional meningioma 10.5 MUC1 NF2
9 optic nerve sheath meningioma 10.5 CDKN2A NF2
10 chordoid glioma 10.4 MUC1 NF2
11 atypical neurofibroma 10.4 CDKN2A NF2
12 optic nerve neoplasm 10.4 CDKN2A NF2
13 cellular schwannoma 10.4 CDKN2A NF2
14 mucinous bronchioloalveolar adenocarcinoma 10.3 CDKN2A MUC1
15 cholangiolocellular carcinoma 10.3 CDKN2A MUC1
16 sarcomatoid mesothelioma 10.3 CDKN2A MUC1
17 ischemic fasciitis 10.3 CDKN2A MUC1
18 well-differentiated liposarcoma 10.3 CDKN2A MUC1
19 dedifferentiated liposarcoma 10.3 CDKN2A MUC1
20 plasmablastic lymphoma 10.3 CDKN2A MUC1
21 meningeal melanocytoma 10.3 CDKN2A MUC1
22 sensory system cancer 10.3 BAP1 CDKN2A
23 biliary tract neoplasm 10.3 CDKN2A MUC1
24 breast scirrhous carcinoma 10.2 EGFR MUC1
25 ocular cancer 10.2 BAP1 CDKN2A
26 anaplastic oligodendroglioma 10.2 CDKN2A EGFR
27 pancreatic ductal carcinoma 10.2 CDKN2A MUC1
28 hepatoid adenocarcinoma 10.2 EGFR MUC1
29 cervical adenosquamous carcinoma 10.2 CDKN2A EGFR
30 malignant pleural mesothelioma 10.2 BAP1 MUC1
31 oropharynx cancer 10.2 CDKN2A EGFR
32 cholecystitis 10.2 CDKN2A MUC1
33 basaloid squamous cell carcinoma 10.2 CDKN2A EGFR
34 melanoma, cutaneous malignant 1 10.1 BAP1 CDKN2A
35 mammary paget's disease 10.1 EGFR MUC1
36 tubular adenocarcinoma 10.1 EGFR MUC1
37 nervous system cancer 10.1 CDKN2A NF2
38 vulva cancer 10.1 CDKN2A EGFR
39 pre-malignant neoplasm 10.1 CDKN2A EGFR
40 small intestinal adenocarcinoma 10.1 EGFR MUC1
41 rhabdoid meningioma 10.1 NF2 VIM
42 penile cancer 10.1 CDKN2A EGFR
43 in situ carcinoma 10.1 CDKN2A EGFR
44 malignant ovarian surface epithelial-stromal neoplasm 10.1 EGFR MUC1
45 ovary epithelial cancer 10.1 EGFR MUC1
46 pharynx cancer 10.1 CDKN2A EGFR
47 adenosquamous carcinoma 10.1 EGFR MUC1
48 ovarian cancer 10.0
49 cervicitis 10.0
50 cervical adenocarcinoma 10.0 CDKN2A EGFR

Graphical network of the top 20 diseases related to Malignant Peritoneal Mesothelioma:



Diseases related to Malignant Peritoneal Mesothelioma

Symptoms & Phenotypes for Malignant Peritoneal Mesothelioma

Human phenotypes related to Malignant Peritoneal Mesothelioma:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 59 32 hallmark (90%) Very frequent (99-80%) HP:0001541
2 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
3 abnormality of coagulation 59 32 occasional (7.5%) Occasional (29-5%) HP:0001928
4 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
5 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
6 peritonitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002586
7 ileus 59 32 occasional (7.5%) Occasional (29-5%) HP:0002595
8 neoplasm 59 32 hallmark (90%) Very frequent (99-80%) HP:0002664
9 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
10 edema of the lower limbs 59 32 occasional (7.5%) Occasional (29-5%) HP:0010741

UMLS symptoms related to Malignant Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 EGFR MUC1 NF2 VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.8 EGFR MUC1 VIM

MGI Mouse Phenotypes related to Malignant Peritoneal Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.72 BAP1 CDKN2A EGFR NF2 VIM
2 muscle MP:0005369 9.56 BAP1 CDKN2A EGFR VIM
3 neoplasm MP:0002006 9.46 BAP1 CDKN2A EGFR NF2
4 reproductive system MP:0005389 9.35 BAP1 CDKN2A EGFR NF2 VIM
5 respiratory system MP:0005388 9.02 BAP1 CDKN2A EGFR NF2 VIM

Drugs & Therapeutics for Malignant Peritoneal Mesothelioma

Drugs for Malignant Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Doxil Approved June 1999 Phase 3,Phase 2 31703
3 Ranpirnase Investigational Phase 3 196488-72-9
4 Topoisomerase Inhibitors Phase 3,Phase 2
5 Anti-Bacterial Agents Phase 3,Phase 2
6 Antibiotics, Antitubercular Phase 3,Phase 2
7
Gemcitabine Approved Phase 2 95058-81-4 60750
8
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
9
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
12
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
13
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
14
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
15
Promethazine Approved, Investigational Phase 2 60-87-7 4927
16
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
17
Fluorouracil Approved Phase 2 51-21-8 3385
18
Pancrelipase Approved, Investigational Phase 2 53608-75-6
19
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
20
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
21
Bevacizumab Approved, Investigational Phase 2 216974-75-3
22
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
23
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
24
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
25
Pembrolizumab Approved Phase 2 1374853-91-4
26
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
28
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
29
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
30 interferons Phase 2,Phase 1
31 Alkylating Agents Phase 2,Phase 1
32 Mitomycins Phase 2
33 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
34 Antibodies Phase 2,Phase 1
35 Immunoglobulins Phase 2,Phase 1
36 Antibodies, Monoclonal Phase 2,Phase 1
37 Immunosuppressive Agents Phase 2,Phase 1
38 Anti-Infective Agents Phase 2,Phase 1
39 Interferon-gamma Phase 2
40 Antimetabolites Phase 2
41 Antiviral Agents Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 2
43 Ranitidine bismuth citrate Phase 2
44 pancreatin Phase 2
45
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
46 Folic Acid Antagonists Phase 2,Phase 1
47 Albumin-Bound Paclitaxel Phase 2,Phase 1
48 Cortisol succinate Phase 2
49 Hydrocortisone 17-butyrate 21-propionate Phase 2
50 Hydrocortisone acetate Phase 2

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
5 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
6 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
7 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
8 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
9 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
10 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
11 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
12 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
13 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
14 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
15 Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting NCT02399371 Phase 2
16 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
17 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
18 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
19 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
20 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Recruiting NCT03436732 Phase 1 LMB-100;SEL-110
21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
22 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
23 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
24 CAR T Cells in Mesothelin Expressing Cancers Active, not recruiting NCT03054298 Phase 1
25 Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Not yet recruiting NCT03546426 Phase 1 Pembrolizumab;Interleukin-2
26 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
27 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
28 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714
29 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
30 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
31 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
32 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Malignant Peritoneal Mesothelioma

Genetic Tests for Malignant Peritoneal Mesothelioma

Anatomical Context for Malignant Peritoneal Mesothelioma

MalaCards organs/tissues related to Malignant Peritoneal Mesothelioma:

41
T Cells, Colon, Pancreas, Lung, Lymph Node, Testis, Liver

Publications for Malignant Peritoneal Mesothelioma

Articles related to Malignant Peritoneal Mesothelioma:

(show top 50) (show all 288)
# Title Authors Year
1
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. ( 29503128 )
2018
2
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. ( 29721724 )
2018
3
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. ( 29651664 )
2018
4
Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. ( 29915796 )
2018
5
Malignant Peritoneal Mesothelioma in the setting of a Ventriculo-Peritoneal Shunt: A novel clinical presentation. ( 29899672 )
2018
6
Malignant peritoneal mesothelioma in patients with endometriosis. ( 29794065 )
2018
7
Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites. ( 29577057 )
2018
8
Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. ( 29506546 )
2018
9
Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis. ( 29643915 )
2018
10
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
11
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
12
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
13
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29019584 )
2017
14
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
15
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% ofA Malignant Peritoneal Mesotheliomas. ( 28034829 )
2017
16
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
17
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
18
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
19
Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy. ( 29027138 )
2017
20
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017
21
Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma. ( 28264807 )
2017
22
Presentation of a malignant peritoneal mesothelioma in the forma of rough hepatic calcifications. ( 28480727 )
2017
23
Epidemiology of malignant peritoneal mesothelioma: A population-based study. ( 29080447 )
2017
24
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2017
25
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
26
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites. ( 28381756 )
2017
27
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. ( 28849389 )
2017
28
Erratum: A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29267565 )
2017
29
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
30
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. ( 28594258 )
2017
31
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma. ( 27858557 )
2016
32
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. ( 27628605 )
2016
33
Renal cell carcinoma and malignant peritoneal mesothelioma after occupational asbestos exposure: case report. ( 27240221 )
2016
34
Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. ( 27281118 )
2016
35
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. ( 26810896 )
2016
36
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. ( 27472649 )
2016
37
Malignant peritoneal mesothelioma and Crohn disease. ( 27484913 )
2016
38
Preventing recurrence of diffuse malignant peritoneal mesothelioma. ( 27486718 )
2016
39
A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype. ( 27438989 )
2016
40
Diagnosis and management of patients with malignant peritoneal mesothelioma. ( 26941986 )
2016
41
Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear: A case report. ( 27773157 )
2016
42
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. ( 27187383 )
2016
43
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. ( 26645426 )
2016
44
Computed Tomographic Features of Malignant Peritoneal Mesothelioma. ( 26976999 )
2016
45
CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis. ( 26661955 )
2016
46
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. ( 27902597 )
2016
47
Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. ( 27612411 )
2016
48
Malignant peritoneal mesothelioma in a patient with intestinal fistula, incisional hernia and abdominal infection: A case report. ( 26998119 )
2016
49
Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. ( 27858561 )
2016
50
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. ( 27858567 )
2016

Variations for Malignant Peritoneal Mesothelioma

Expression for Malignant Peritoneal Mesothelioma

Search GEO for disease gene expression data for Malignant Peritoneal Mesothelioma.

Pathways for Malignant Peritoneal Mesothelioma

Pathways related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.81 CDKN2A EGFR VIM
2 11.41 BAP1 MUC1 NF2 VIM
3 11.18 CDKN2A EGFR
4 11.18 CDKN2A EGFR NF2
5 10.96 CDKN2A EGFR

GO Terms for Malignant Peritoneal Mesothelioma

Biological processes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of protein stability GO:0031647 9.16 CDKN2A NF2
2 negative regulation of cell proliferation GO:0008285 9.13 BAP1 CDKN2A NF2
3 negative regulation of cell-matrix adhesion GO:0001953 8.62 CDKN2A NF2

Sources for Malignant Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....